NBI 42902

Drug Profile

NBI 42902

Latest Information Update: 28 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurocrine Biosciences
  • Class Pyrimidinones; Small molecules
  • Mechanism of Action Gonadotropin releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Benign prostatic hyperplasia; Breast cancer; Endometriosis; Prostate cancer; Uterine leiomyoma

Most Recent Events

  • 07 Jul 2006 This compound is still in active development
  • 01 Jul 2005 Data presented at the 87th Annual Meeting of the Endocrine Society (ENDO-2005) have been added to the Women's health pharmacodynamics section
  • 31 Jan 2005 Phase-I clinical trials in Benign prostatic hyperplasia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top